9:04AM Cadence Pharma: New data detailing economic impact of IV Acetaminophen in Treating acute pain to be presented at two major healthcare conferences. Co finds the research is very encouraging (CADX) 9.53 : Co announces that results from a new study analyzing large-scale hospital billing data will be presented today at two major healthcare conferences. The study examined the impact of Cadence's IV acetaminophen therapy, OFIRMEV injection, on certain healthcare-related outcomes in the perioperative setting. The study evaluated data from more than 22,000 inpatient admissions for major joint repair procedures from a hospital research database of more than 550 hospitals maintained by the Premier healthcare alliance. In the analysis, 11,073 patients who underwent elective major joint arthroplasty and who received OFIRMEV on the day of surgery were matched to 11,073 patients who did not receive the treatment during their stay. Researchers compared data from the two groups to assess differences in certain patient outcomes, including hospital length-of-stay, and average hospital costs.
Co's Commentary: "This research is very encouraging and demonstrates how integrating IV acetaminophen as a foundation for multimodal surgical analgesia may positively impact the cost of care and outcomes for surgical patients...Multiple medical societies have endorsed multimodal analgesia to optimize pain outcomes while reducing opioid use in order to minimize side effects often seen with narcotics. We look forward to working with medical professionals to help implement multimodal treatment strategies."
